News Headlines Article

Genentech Alzheimer’s drug crashes in clinical trial … maybe
San Francisco Business Times

An experimental Alzheimer’s disease drug by Genentech Inc. and Swiss partner AC Immune failed to hit both of its main targets, but it appeared to show some benefit for patients with a milder form of the disease. The mixed results of the mid-stage are a blow to South San Francisco-based Genentech, which has seen the alliance with AC Immune as a cornerstone of its expansion beyond cancer into neuroscience. Genentech parent Roche now must determine if it will take the drug, called crenezumab, further in clinical studies.